Data as of Aug 01
| -0.20 / -4.73%|
The 3 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 6.00, with a high estimate of 7.00 and a low estimate of 5.00. The median estimate represents a +48.88% increase from the last price of 4.03.
The current consensus among 4 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.